Some genetics experts felt the event raised awareness of the importance of testing, while others had mixed feelings amid growing healthcare access worries.

Galapagos is collecting bids for its cell therapy business, and its board will announce its decision on selling the business by Nov. 5.

The firm will use the funding to launch its T-cell engager candidate into clinical trials early next year in LY6G6D-expressing colorectal cancer.

The drugmaker has launched an international Phase I trial, dubbed Breakfree-2, in seven countries to test the autologous therapy.

Investigators are assessing whether treatment with the angiotensinogen-targeting RNAi agent reduces patients' risk of cardiovascular disease.

The drugmaker is transitioning to Trialbee's Honey platform to better screen patients, including for biomarker information, ...

The study found that patients with luminal B subtype prostate cancer benefited from the addition of hormone therapy to ...

Half of US commercial health plans add coverage limits for gene and cell therapies beyond what they're approved for, ...

Patients with HER2-positive tumors fared better on neoadjuvant Enhertu followed by chemo and a dual anti-HER2 antibody regimen than those on standard treatment.

In the meeting, the firm will discuss with the agency new, positive three-month data from the pediatric cohort of the Phase I/II OPGx-LCA5-1001 trial.

The new biotech is developing an antibody-oligo conjugate platform that uses "brain shuttles" to deliver drugs across the blood-brain barrier.

In an increasingly crowded space, the firm is using streamlined manufacturing and lipid nanoparticle delivery for its in vivo ...